Min Su Kim, Young-Joo Jin, Jin-Woo Lee, Jung-il Lee, Young soo Kim, Sun young Lee, Myoung Hun Chae, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon 400-711, South Korea.
World J Gastrointest Oncol. 2013 Feb 15;5(2):38-42. doi: 10.4251/wjgo.v5.i2.38.
Hepatocellular carcinoma (HCC) is the fifth most common malignant disease worldwide, and curative treatment remains difficult because the majority of cases are diagnosed in the advanced stage. Sorafenib is the only known effective systemic treatment, but patients rarely achieve complete remission (CR). A 66-year-old man with a history of alcoholic liver cirrhosis with a diagnosis of advanced HCC, was initially treated with transarterial chemoembolization on four occasions. However, the disease progressed with portal vein thrombosis. Therefore, sorafenib was started, and 4 mo later, the patient achieved CR. The treatment was continued for 12 mo, and CR was maintained up to 4 mo after sorafenib discontinuation.
肝细胞癌(HCC)是全球第五大常见恶性疾病,由于大多数病例在晚期诊断,因此有效的治疗方法仍难以实现。索拉非尼是目前唯一已知的有效系统治疗药物,但患者很少能达到完全缓解(CR)。一名 66 岁男性,有酒精性肝硬化病史,诊断为晚期 HCC,最初接受了 4 次经动脉化疗栓塞治疗。然而,疾病进展并出现门静脉血栓形成。因此,开始使用索拉非尼治疗,4 个月后患者达到 CR。该治疗持续了 12 个月,并且在停用索拉非尼后 4 个月内仍维持 CR。